CD52 and B-cell chronic lymphocytic leukemia: Alemtuzumab, a humanized IgG1 kappa mAb targeting CD52 antigen expressed on both benign and malignant B and T cells, monocytes, macrophages, natural killer cells and a proportion of granulocytes [143] has originally been approved for the treatment of chronic lymphocytic leukemia (CLL).